Silence Therapeutics plc (SLN) research
Silence Therapeutics plc- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $11.22
- As of
Silence Therapeutics plc (SLN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.
As of . Source: SEC EDGAR filings for SLN. Method and limitations.
Share the SLN intelligence card
See SLN live in the terminal
Track SLN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live SLN terminal, freeActive signals for SLN
- highCONSENSUS_BUY
3 tracked funds increased SLN this 2026Q2, institutional consensus
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in SLN
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8884% to SLN (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +647% to SLN (2026Q2)
- highCONSENSUS_BUY
3 tracked funds increased SLN this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every signal on SLN, as it fires
You are seeing 5 of 16 signals recorded on SLN since 2026-07-24.
The five above all landed on 2026-09-06. The other 11 were recorded on 2 other days. 13 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SLN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 82686Q101 · 2026Q2 | $14.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 82686Q101 · 2026Q2 | $10M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 82686Q101 · 2026Q2 | $1.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 82686Q101 · 2026Q2 | $186K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SLN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
SLN against its peers
SLN's operating margin of -16292.8% ranks in the 10th percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SLN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 559000 USD | 106M USD | 16 | 15 |
| Gross margin | 61.5% | n/a | n/a | 2 |
| Operating margin | -16292.8% | -6.7% | 10 | 14 |
| Net margin | -15851.9% | 4.4% | 10 | 14 |
| Return on equity | -142.2% | -36.9% | 16 | 21 |
| P / E | n/a | 11.7x | n/a | 6 |
Peers (22): DBVT, ZVRA, ANNX, PHAR, IRWD, GYRE, NVCT, XOMA, ACHV, DSGN, MDXG, SGMT, FDMT, GERN, VSTM, WVE, OLMA, AURA, RIGL, ARDX, TBPH, AVTX. Left out: ETRA (no annual filing), ATTO (no annual filing), BLSM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SLN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SLN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SLNand get the insider, 13F, options, and confluence read in one view.